Published in Oncol Res on January 01, 1997
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25
Hypoxic preconditioning protects against ischemic brain injury. NeuroRx (2004) 1.44
Physiology and pathophysiology of SLC12A1/2 transporters. Pflugers Arch (2013) 0.96
RNAi screen for telomerase reverse transcriptase transcriptional regulators identifies HIF1alpha as critical for telomerase function in murine embryonic stem cells. Proc Natl Acad Sci U S A (2010) 0.96
Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1α protein synthesis. PLoS One (2014) 0.87
'In vivo' optical approaches to angiogenesis imaging. Angiogenesis (2010) 0.85
Gene delivery to hypoxic cells in vitro. Br J Cancer (2000) 0.79
17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response. Br J Cancer (2002) 0.78
Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. J Toxicol Pathol (2009) 0.78
Five-minute Apgar score ≤ 5 and Molar Incisor Hypomineralisation (MIH) - a case control study. BMC Oral Health (2016) 0.75
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 19.75
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Characterization of nonlymphoid cells derived from rat peripheral lymph. J Exp Med (1983) 5.63
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem (2000) 5.58
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J (2001) 5.20
Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol (1995) 4.72
Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. Proc Natl Acad Sci U S A (1994) 4.10
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro. Br J Cancer (1977) 3.51
Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res (1976) 3.44
Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci U S A (1993) 3.29
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27
Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem (1997) 3.23
Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem (1995) 2.89
The distribution, ontogeny and origin in the rat of Ia-positive cells with dendritic morphology and of Ia antigen in epithelia, with special reference to the intestine. Eur J Immunol (1983) 2.87
Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem (1995) 2.80
The rat mixed lymphocyte reaction: roles of a dendritic cell in intestinal lymph and T-cell subsets defined by monoclonal antibodies. Immunology (1981) 2.75
Trans-ethnic fine mapping of a quantitative trait locus for circulating angiotensin I-converting enzyme (ACE). Hum Mol Genet (2001) 2.75
Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. Proc Natl Acad Sci U S A (1991) 2.67
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet (2001) 2.56
Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet (1998) 2.53
Activation of the HIF pathway in cancer. Curr Opin Genet Dev (2001) 2.38
Morphogenesis and fine structure of Frankia (Actinomycetales): the microsymbiont of nitrogen-fixing actinorhizal root nodules. Int Rev Cytol (1987) 2.36
The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem (1996) 2.30
Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha. J Biol Chem (1999) 2.28
Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res (2001) 2.12
Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int (1993) 2.07
HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene (2007) 2.00
Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney. Proc Natl Acad Sci U S A (1996) 2.00
Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. Eur Heart J (2002) 1.89
Targeting gene expression to hypoxic tumor cells. Nat Med (1997) 1.82
Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol (1998) 1.78
Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alpha-dependent and -independent hypoxia-inducible gene expression. J Biol Chem (1998) 1.78
Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) (1987) 1.69
The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev (1993) 1.59
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene (2000) 1.57
The interaction of misonidazole with radiation, chemotherapeutic agents, or heat: a preliminary report. Cancer Clin Trials (1980) 1.54
Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood (2001) 1.54
Mammalian cell toxicity of nitro compounds : dependence upon reduction potential. Biochem Biophys Res Commun (1976) 1.53
Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br J Cancer (2007) 1.50
Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol (1995) 1.50
Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol (2001) 1.48
Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. Int J Radiat Biol Relat Stud Phys Chem Med (1979) 1.47
Induction of severe tumor hypoxia by modifiers of the oxygen affinity of hemoglobin. Int J Radiat Oncol Biol Phys (1989) 1.45
Agent-based computational modeling of wounded epithelial cell monolayers. IEEE Trans Nanobioscience (2004) 1.45
Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology (1985) 1.44
Rapid genetic analysis of families with polycystic kidney disease 1 by means of a microsatellite marker. Lancet (1991) 1.44
Age-dependent expression of the erythropoietin gene in rat liver and kidneys. J Clin Invest (1992) 1.43
Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet (1991) 1.42
Screening and treatment to prevent post abortion chlamydial pelvic infection. Lancet (1989) 1.42
Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur J Biochem (1996) 1.41
The toxicity of the radiosensitizer misonidazole towards hypoxic cells in vitro: a model for mouse and man. Br J Radiol (1978) 1.40
Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer (2004) 1.39